In a report released today, Suraj Kalia from Oppenheimer maintained a Buy rating on Humacyte (HUMA – Research Report). The company’s shares closed last Friday at $3.04.
Kalia covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, TransMedics Group, and Butterfly Network. According to TipRanks, Kalia has an average return of 5.6% and a 51.87% success rate on recommended stocks.
Currently, the analyst consensus on Humacyte is a Strong Buy with an average price target of $8.00, a 163.16% upside from current levels. In a report released on March 28, TD Cowen also reiterated a Buy rating on the stock with a $5.00 price target.
Based on Humacyte’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $25.11 million. In comparison, last year the company had a GAAP net loss of $3.72 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Humacyte (HUMA) Company Description:
Alpha Healthcare Acquisition Corp is a blank check company.
Read More on HUMA:
- Humacyte management to meet with BTIG
- Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024
- Options Volatility and Implied Earnings Moves Today, March 22, 2024
- Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
- Humacyte reports Q4 EPS (24c), consensus (24c)
